Skip to content
Annika Bansal – Lifestyle
Author:
Alumis Inc.
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
March 28, 2026
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
March 20, 2026
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
March 18, 2026
Alumis to Present at the Leerink Partners Global Healthcare Conference
March 5, 2026